Register

Registration

Note : After Answered of Questionnaires / Survey Please Close it.
.

Bal Pharma Ltd . Small Cap

BSE: 524824 | NSE: BALPHARMA
Pharmaceuticals
Live
20/04/2021 4:00:00 PM
72.05 11.65   (19.29%)
BSE: price shown with 5 mins delayed.
Prev. Close 60.40
Open Price 60.75
Volume Traded 158389.00

Fundamentals

Mar'11 Mar'12 Mar'13 Mar'14 Mar'15 Mar'16 Mar'17 Mar'18 Mar'19 Mar'20
Ajusted EPS(Rs.) 0.39 4.4 2.56 0.2 0 0.27 1.52
Net Sales (Rs. Cr.) 114.29 178.87 187.16 198.31 228.91 211.48 225.01
Adjusted Net Profit 0.41 5.08 3.55 0.25 -0.390000000000001 0.380000000000001 2.14
Book Value/ Share(Rs.) 34.51 43.48 41.32 41.09 44.06 45.86 47.02
Cash Flow 0.62 -1.51 2.43 -0.86 -7.59 0.55 -0.27
Debt to Cash Flow from Operations 12.52 3.81 3.41 -4.59 14.76 188.84 15.91
RONW 1.14 10.13 6.75 0.47 -0.68 0.60 3.27
ROCE % 9.04 13.45 10.75 7.19 7.43 7.30 6.82
Net Operating Profit Margin % 3.37 6.25 6.17 4.77 3.99 4.56 2.64
Net Profit Margin % 0.35 2.79 1.86 0.13 -0.17 0.18 0.96
Debt / Equity 1.56 1.01 0.95 1.26 1.55 1.59 1.77
Dividend Yield % 0.00 3.19 1.50 1.09 1.26 1.52 2.28
Mar'11 Mar'12 Mar'13 Mar'14 Mar'15 Mar'16 Mar'17 Mar'18 Mar'19 Mar'20
Ajusted EPS(Rs.) 0.45 3.56 3.92 4.4 2.93 1.96 3.55 4.19 4.77 0
Net Sales (Rs. Cr.) 114.44 139.69 147.92 178.87 187.13 197.65 225.96 209.85 223.08 170.67
Adjusted Net Profit 0.47 3.00 4.28 5.08 4.01 2.80 5.32 5.94 6.76 -8.90
Book Value/ Share(Rs.) 34.83 37.89 41.06 43.48 41.63 42.48 46.98 50.97 54.23 46.53
Cash Flow 0.35 1.06 1.50 -1.51 1.51 -0.07 0.14 0.51 -0.38 -1.53
Debt to Cash Flow from Operations 5.11 4.42 3.30 3.81 3.44 54.48 11.65 7.20 9.05 4.61
RONW 0.00 0.00 10.11 10.71 7.61 5.00 8.61 8.56 9.07 -12.46
ROCE % 8.71 11.19 13.13 13.57 11.16 9.85 12.42 11.48 9.74 2.03
Net Operating Profit Margin % 3.87 5.36 6.59 6.25 6.40 6.03 6.49 7.23 4.72 -1.20
Net Profit Margin % 0.40 2.11 2.85 2.79 2.11 1.39 2.29 2.83 3.03 -5.21
Debt / Equity 1.55 1.50 1.31 1.10 0.95 1.06 1.17 1.19 1.31 1.43
Dividend Yield % 0.00 0.00 4.15 3.19 1.50 1.09 1.26 1.52 2.28 0.00

Year on Year Growth Rate (%)

Ajusted EPS Sales Adjusted Net Profit

Latest Financials

Standalone Consolidated
TTM EPS (Rs) 0.39 0
TTM Sales (Rs. Cr.) 212.8 213.49
BVPS (Rs.) 48.82 38.13
Reserves (Rs. Cr.) 57.54 41.7
P/BV 1.48 1.89
PE 184.74 NM
From the Market
52 Week High / Low (Rs) 73/33.5
All Time High / Low (Rs) 167.9/1.6
Volume Traded 158389
Market Cap (Rs. Cr.) 106.8
Equity (Rs. Cr.) 14.822372
Face Value (Rs) 10
Industry PE 0

Quarterly Results

Mar'2020 Jun'2020 Sep'2020 Dec'2020
Net Sales (Cr) 33.77 52.05 64.28 62.70
Adjusted EPS (Rs) -2.92 1.16 1.08 1.09
Net Profit Margin % -12.26 3.15 2.38 2.47
Mar'2020 Jun'2020 Sep'2020 Dec'2020
Net Sales (Cr) 33.77 52.13 64.56 63.03
Adjusted EPS (Rs) -3.35 0.20 0.30 0.23
Net Profit Margin % -14.04 0.54 0.65 0.51

Quarterly Growth Rate (%)

Ajusted EPS Sales Net Profit Margin

Peers Data

Name Current Price(Rs) Market Cap. (Rs. cr.) Net Profit(Rs. cr.) Sales Growth(%)
Gujarat Terce Laboratories Ltd 7.23 5.36 0.28 -48.69
Parnax Lab Ltd 19.2 16.32 0 -79.17
Medi Caps Ltd 39.25 48.94 -8.33 -100.00
Vivo Bio Tech Ltd 57.2 77.99 4.44 -35.53
Lyka Labs Ltd 29.45 84.49 -53.19 -10.42
Bal Pharma Ltd 72.05 106.8 -8.9 4.89
Aurobindo Pharma Ltd 987.4 57855.58 1872.74 -11.37
Cipla Ltd 949.3 76557.56 2318.17 -39.44
Dr Reddys Laboratories Ltd 5153.95 85710.93 2937.7 -15.73
Divis Laboratories Ltd 3783.8 100448 1372.71 -4.34
Sun Pharmaceuticals Industries Ltd 645.05 154769.1 3211.14 -20.62

Technical

Sector

23387.09 280.75   (1.22%)

Index

47705.80 -243.62   (-0.51%)
9 Days Avg
Span A Span B 52 Week TenKan-Sen Kijun-Sen ChiKou-Sen
9 Days Avg

Score

Kindly subscribe to get access

Research Analytical

Kindly subscribe to get access

News

About Company

Bal Pharma (BPL), a member of the Mcro Laboratories group, was incorporated as a private limited company in May '87. In Mar.'90, BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which, BPL commenced manufacturing formulations.BPL manufactures and markets pharmaceutical formulations -- paracetamol, aluminium hydroxide, povidone iodine, alprazolam, gliclazide, griseofulvin, lactobacillus, rifampicin, piroxicam amoxycillin, etc. The company promotes its products through the common sales force of the group but proposes to induct its own soon. It came out with a public issue in Feb.'95 for manufacture of bulk drugs and expansion of pharmaceutical formulations.During 1997-98, the formalities of takeover of the unit from Lakme Limited have been completed and effective from 23rd July, 1997 the unit has become a division of Bal Pharma Limited. The company's product range has been expanded with the introduction of AZIWIN, CAFIMOL & CORTIDERM.The company has added further product range Zanovid, Aziwin, Dry Syrup, Meloxi, Ocium - M, Progit - MPS in its ethical division during 1999-2000. As part of the expansion of the product range, the company has introduced Cardiac Specialities Products. To market these products, a new division named SERVETUS has started functioning during 2001. New products like Amiloride,Benzydamine and Ebastine were rolled into the market during 2002.